NCT07512609 Environment, Inflammation and Metabolic Diseases Study
| NCT ID | NCT07512609 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qifu Li |
| Condition | Endocrine Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 8,000 participants |
| Start Date | 2020-12-25 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8,000 participants in total. It began in 2020-12-25 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim is to establish an effective and practical early warning model for endocrine and metabolic diseases based on an environmental-gene-protein panoramic network, to uncover new mechanisms underlying the onset and progression of these diseases, and to screen for novel therapeutic targets.
Eligibility Criteria
Inclusion Criteria: * All individuals who voluntarily participated in the physical examination Exclusion Criteria: Participants with incomplete data
Contact & Investigator
Qifu Li, MD, PhD, Chief Physician
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Chongqing Medical University
Frequently Asked Questions
Who can join the NCT07512609 clinical trial?
This trial is open to participants of all sexes, studying Endocrine Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07512609 currently recruiting?
Yes, NCT07512609 is actively recruiting participants. Contact the research team at liqifu@yeah.net for enrollment information.
Where is the NCT07512609 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT07512609 clinical trial?
NCT07512609 is sponsored by Qifu Li. The principal investigator is Qifu Li, MD, PhD, Chief Physician at First Affiliated Hospital of Chongqing Medical University. The trial plans to enroll 8,000 participants.